In summary, our data uncover that targeting BCL9/BCL9L plays a key role in cDC1-regulated presentation of tumor-derived antigens and subsequently in cDC1-triggered activation and tumor infiltration of CD8+ T cells, constituting a positive feedback loop required for optimal antitumor immunity. This evidence concerns the gene BCL9 and neoplasm.